medigraphic.com
ISSN 1990-7990 (Electronic)
Revista Universitaria

2022, Number 1

<< Back Next >>

Universidad Médica Pinareña 2022; 18 (1)

Update on the pathophysiology, diagnosis and treatment of priapism

Rodríguez-Venegas EC, Denis-Piedra DA, Hernández-García OL

Language: Spanish
References: 24
Page: 1-8
PDF size: 167.98 Kb.


ABSTRACT

Introduction: priapism is defined as a prolonged and persistent erection of the penis that is unrelated to sexual desire; it can last more than 4 hours and constitutes a medical emergency. The incidence recorded in the general population is 1,5 cases per 100,000 persons per year and in those over 40 years of age it reaches 2,9.
Objective: to describe the pathophysiology, diagnosis and treatment of priapism.
Method: a search for information was carried out in English and Spanish, consulting the Pubmed, SciELO, Lilacs, Cochrane Library and Web of Science databases. Twenty-four articles were chosen for the development of this review.
Development: there are two pathophysiological variants of priapism, ischemic or low-flow priapism, which causes pain and is an emergency, which can lead to permanent erectile dysfunction, and non-ischemic or high-flow priapism. Diagnosis is mainly clinical, although tests that evaluate blood flow, such as Doppler ultrasound, are useful. Therapeutic management will depend on the cause of priapism and the time elapsed since the onset of the condition.
Conclusions: priapism is a rare disease, with different forms of presentation depending on the etiology; where this determines the symptoms, evolution and damage to the male reproductive organ. Diagnosis is mainly clinical, although techniques such as Doppler ultrasound are useful. Therapeutic alternatives vary from primary administration of anti-androgens to surgical alternatives such as shunts and cavernostomy.


REFERENCES

  1. Reed-Maldonado AB, Lue TF. Modern Strategies for the Surgical Treatment of Priapism. En: Martins FE, Kulkarni SB, Köhler TS. Textbook of Male Genitourethral Reconstruction [Internet]. Switzerland: Springer Nature; 2020 [citado 05/09/2020]. Disponible en: https://doi.org/10.1007/978-3-030-21447-0_42

  2. Casanova López G. Otros estadíos patológicos. Priapismo. En: Colectivo de Autores. Temas de Urología. La Habana: Editorial Ciencias Médicas; 2008. pp. 286-288.

  3. Castro Maldonado O, Meléndez Borges JE, Pedro Silva IE, Mirabal Fariñas AM, Rodríguez Morales A. Caracterización epidemiológica, diagnóstica y terapéutica de pacientes con priapismo. MEDISAN [Internet]. 2016 [citado 05/09/2020]; 19(10):1238. Disponible en: http://www.medisan.sld.cu/index.php/san/article/view/474

  4. Roque García W. Fisiopatología del priapismo en el paciente con anemia Drepanocítica. Revista Cubana de Hematología, Inmunol y Hemoter. [Internet]. 2016 [citado 05/09/2020];32(4): [aprox 9 pag]. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892016000400003

  5. Hinman F. Priapism: report of cases and a clinical study of the literature with references to its pathogenesis and surgical treatment. Ann Surg [Internet]. 1914 [citado 05/09/2020]; 60:689-716. Disponible en: http://doi.org/10.1097/00000658-191412000-00004.

  6. Rezaee ME, Gross MS. Are We Overstating the Risk of Priapism With Oral Phosphodiesterase Type 5 Inhibitors? J Sex Med [Internet]. 2020 [citado 05/09/2020]; [In Press]. Disponible en: https://doi.org/10.1016/j.jsxm.2020.05.019

  7. Balparda-Arias JK. Priapismo: concepciones clínicas, diagnósticas y de tratamiento. Gac Med Bilbao. [Internet]. 2010 [citado 05/09/2020]; 107(4):128-135. Disponible en: https://www.elsevier.es/index.php?p=revista&pRevista=pdf-simple&pii=S0304485810700330

  8. Carrillo-Córdova LD, Acevedo-García C, Rivera-Astorga H, Garduño-Arteaga LM. Priapismo: comorbilidades, tratamiento, complicaciones y función sexual de los pacientes. Rev Mex Urol. [Internet]. 2020 [citado 05/09/2020]; 77(5):383-388. Disponible en: https://doi.org/10.24245/revmexurol.v77i5.1120

  9. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract [Internet]. 2018 [citado 05/09/2020]; 64:240-255. http://refhub.elsevier.com/S1743-6095(20)30656-1/sref4

  10. Broderick GA. Priapism. En: Wein AJ. Campbell-Walsh Urology. 10th ed. Philadelphia: Saunders Elsevier; 2018. pp. 25.

  11. Castaño JC, Carvajal A. Priapismo. En: Uribe JF, Flórez F, editores. Urología. 3.ª edición. Medellín: Corporación para Investigaciones Biológicas; 2017. pp. 294-300.

  12. Lagoda J, Sezen SF, Cabrini MR, Musicki B,Burnett AL. Molecular Analysis of Erection Regulatory Factors in Sickle Cell Disease Associated Priapism in the Human Penis. J Urol [Internet]. 2018 [citado 05/09/2020]; 189(2):762-68. Disponible en: http://doi.org/10.1016/j.juro.2012.08.198

  13. Fukata Y, Amano ME, Koibuchi K. Rho-Rho kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci [Internet]. 2001 [citado 05/09/2020]; 22(1):32-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11165670/

  14. Anele UA, Morrison BF, Burnett AL. Molecular pathophysiology of priapism: Emerging targets. Curr Drugs Targets [Internet]. 2016 [citado 05/09/2020]; 16(5):474-83. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4430197/

  15. Mwamukonda KB, Chi T, Shindel AW. Androgen blockade for the treatment of high-flow priapism. J Sex Med [Internet]. 2017 [citado 05/09/2020]; 7:2532–7. Disponible en: http://doi.org/10.1111/j.1743-6109.2010.01838.x

  16. Ridgley J, Raison N, Sheikh MI. Ischaemic priapism: a clinical review. Turk J Urol [Internet]. 2018 [citado 05/09/2020]; 43(1):1–8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28270944/

  17. Salonia A, Eardley I, Giuliano F. European Association of Urology guidelines on priapism. Eur Urol. [Internet]. 2017 [citado 05/09/2020]; 65:480–9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24314827/

  18. Broseta E, Judia A, Burgues JP, Luján S, Jiménez Cruz JF. Urgencias en Urología. Priapismo. En: Urología Práctica. 3 ed. España: Editorial EneEdiciones; 2011. p. 36-8.

  19. Lue TF, Garcia M. Should perioperative anticoagulation be an integral part of the priapism shunting procedure? Transl Androl Urol [Internet]. 2017 [citado 05/09/2020]; 2:316. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4708115/

  20. Reed-Maldonado AB, Kim JS, Lue TF. Avoiding complications: surgery for ischemic priapism. Transl Androl Urol. [Internet]. 2017 [citado 05/09/2020]; 6:657–65. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28904898/

  21. Muneer A, Alnajjar HM, Ralph D. Recent advances in the management of priapism. F1000Res [Internet]. 2018 [citado 05/09/2020]; 7:37. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765390/

  22. Burnett AL, Anele UA, Trueheart IN, Strouse JJ, Casella JF. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med [Internet]. 2014 [citado 05/09/2020]; 127:664–8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24680796/

  23. Lamamri, AM. Chebbi, J. Mamane. Priapism in a patient with coronavirus disease 2019 (COVID-19): A case report. Am J Emerg Med [Internet]. 2020 [citado 05/09/2020]; [In Press]. Disponible en: https://doi.org/10.1016/j.ajem.2020.06.027

  24. Leisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med [Internet]. 2020 [citado 05/09/2020]; 46 (6): [aprox 9 pag]. Disponible en: https://doi.org/10.1007/s00134-020-06059-6




2020     |     www.medigraphic.com